Forecast

The analysts' average price target is +55,82€ (+1.271,50%). The median is +35,64€ (+775,68%).

Buy	5
Hold	13
Sell	2

News Go to news feed

Tilray Brands posts record fiscal 2026 revenue but shares fail to rally

Tilray Brands reported record fiscal 2026 revenue of about $915 million and an 11% rise in adjusted EBITDA to $61.1 million, with adjusted net income nearly doubling to $12.2 million. The results nonetheless missed sell-side forecasts and the company recorded a GAAP net loss of $49.6 million. Management guided to modest adjusted EBITDA growth for fiscal 2027 and has reduced debt largely through dilutive debt-for-equity swaps, while cannabis now represents only 29% of sales, leaving investors hesitant to drive the stock higher. » More on finance.yahoo.com
Tilray increases global cultivation capacity for medical cannabis to around 275 tonnes

Tilray has expanded its annual cultivation capacity from 210 to about 275 tonnes, mainly through production increases in Quebec and at the EU‑GMP‑certified plant in Portugal. Quebec now supplies large volumes to sites in Portugal and Australia, is aiming for EU‑GMP certification within 12 months and has built up inventories for international markets. In Germany the Aphria RX facility is running at full capacity and the new ARX brand has been launched, strengthening Tilray’s supply infrastructure for Europe, the UK and other regulated markets. » More on finanzen.net
Tilray to stop brewing at Terrapin site and shift production within US network

Tilray will cease beer production at its Terrapin brewery in Athens, Georgia and move brewing to other facilities in its US network from 25 September as part of efforts to optimise its brewing operations. The taproom, warehouse and repack operations in Athens will remain open and Terrapin will stay in Tilray’s craft beer portfolio. The change follows broader beverage restructuring under ‘Project 420’, which has included facility closures, brand adjustments and disposals aimed at improving profitability; Tilray reported beverage net revenue of $254m for the year to 31 May 2026, with gross profit of $91.2m. » More on finance.yahoo.com

Historical dividends Dividends

All dividend metrics All metrics

In 2022, Tilray has already paid 0,10€ in dividends. The last payout was in June 2022.

Financials

In the last quarter, Tilray had revenue of 241.83m€ and net profit of −42.55m€

(EUR)	May 2026	YoY
Revenue	+241.83m	10,93%
Gross profit	+72.39m	11,49%
Net profit	−42.55m	97,24%
EBITDA	+12.75m	100,78%

Fundamentals

Metric	Value
Market capitalization	+453.25m€
Number of shares	111.83m
52-week high/low	+19,92€ - +3,15€
Dividends	No
Beta	1,91
P/E ratio	−3,54
PEG ratio	−0,02
P/B ratio	+0,33
P/S ratio	+0,46

Company profile

Tilray Brands Inc. beschäftigt sich mit der Forschung, dem Anbau, der Produktion, dem Marketing und dem Vertrieb von medizinischen Cannabisprodukten. Das Unternehmen ist in fünf Segmenten tätig: Cannabis Business, Distribution Business, Beverage Alcohol Business, Wellness Business, und Business Under Development. Das Unternehmen bietet medizinische und für Erwachsene bestimmte Cannabisprodukte, pharmazeutische und Wellness-Produkte, alkoholische Getränke sowie hanfbasierte Lebensmittel und andere Wellness-Produkte an. Es bietet seine Produkte Einzelhändlern, Großhändlern, Patienten, Ärzten, Apotheken, Kliniken, Krankenhäusern, Regierungen und Forschern an. Das Unternehmen betreibt Tilray Medical, eine medizinische Plattform, die GMP-zertifizierte Blüten, Öle, Vapes, Esswaren und topische Produkte anbietet. Es hat Niederlassungen in Kanada, den Vereinigten Staaten, Europa, Australien, Neuseeland, Lateinamerika und international. Das Unternehmen war früher unter dem Namen Tilray, Inc. bekannt. Tilray Brands Inc. wurde im Jahr 2018 gegründet und hat seinen Hauptsitz in New York, New York.